A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti‐CD40 monoclonal antibody, in kidney transplantation. Issue 1 (9th September 2019)

• Record Type: Journal Article
• Authors: Vincenti, Flavio; Klintmalm, Goran; Yang, Harold; Ram Peddi, V.; Blahunka, Paul; Conkle, Angela; Santos, Vicki; Holman, John
• Is Part Of: American journal of transplantation. Volume 20:Issue 1(2020)
• Page Start: 172
• Page End: 180
• Publication Date: 2019-09-09
• Subjects: antibody biology -- clinical research/practice -- kidney transplantation/nephrology -- kidney transplantation: living donor; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.15560
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of various doses of the anti‐CD40 monoclonal antibody bleselumab (ASKP1240) in de novo kidney transplant recipients receiving concomitant standard immunosuppression over 90 days posttransplant. Transplant recipients were randomized (1:1:1:1:1) to bleselumab 50 mg, 100 mg, 200 mg, or 500 mg, or placebo, in addition to standard maintenance immunosuppression. The primary pharmacokinetic endpoints were AUCinf, C max, and AUClast . The primary pharmacodynamic endpoint was B cell CD40 receptor occupancy over time. Overall, 50 kidney transplant recipients were randomized; 45 received their randomized treatment (bleselumab [n = 37] or placebo [n = 8]). AUCinf and AUClast demonstrated a more than dose‐proportional increase in the range of 50‐500 mg, and C max increased linearly with increasing dose. Maximal receptor occupancy for B cell CD40 was reached at all dose levels and was prolonged as dose increased. No kidney transplant recipients experienced cytokine release syndrome or a thromboembolic event. Treatment‐emergent anti‐bleselumab antibodies were found in one kidney transplant recipient in the bleselumab 50 mg group; these were detected only at Day 7. Overall, bleselumab demonstrated nonlinear pharmacokinetics and dose‐dependent prolonged B cell CD40 receptor occupancy and was well tolerated at all doses (ClinicalTrials.gov: NCT01279538). Abstract : In this randomized, phase 1b study in kidney transplant recipients, bleselumab, a nondepleting, fully human, anti‐CD40 monoclonal antibody, demonstrates tolerability, nonlinear pharmacokinetics, and prolonged, dose‐dependent B‐cell CD40 receptor occupancy. See the article by Harland et al on page 159 .